Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
In: Open Medicine, Jg. 11 (2016), Heft 1, S. 374-380
Online
academicJournal
Zugriff:
Autoimmune hemolytic anemia (AIHA) is a rare hematologic disease, primarily affecting adults or children with immunodeficiency disease. First-line therapy consists of long course of steroids administration, with an early complete response rate (CRr) of 75-80%, but up to 20-30% of patients requires a second-line therapy. Rituximab is the first choice in refractory old AIHA patients, because of its safety and efficacy (early CRr at 80-90% and at 68% at 2-3 years). For this reason, splenectomy is even less chosen as second-line therapy in elderly, even though laparoscopic technique decreased complication and mortality rates. However, splenectomy can be still considered a good therapeutic option with a CRr of 81% at 35.6 months in patients older than 60 year-old, when rituximab administration cannot be performed.
Titel: |
Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
|
---|---|
Autor/in / Beteiligte Person: | Valentina, Giudice ; Rosa, Rosamilio ; Idalucia, Ferrara ; Elisa, Seneca ; Bianca, Serio ; Carmine, Selleri |
Link: | |
Zeitschrift: | Open Medicine, Jg. 11 (2016), Heft 1, S. 374-380 |
Veröffentlichung: | De Gruyter, 2016 |
Medientyp: | academicJournal |
ISSN: | 2391-5463 (print) |
DOI: | 10.1515/med-2016-0068 |
Schlagwort: |
|
Sonstiges: |
|